Abstract:G protein-coupled receptor 120 (GPR120) is a Gαq coupled GPCR specifically activated by long-chain fatty acids (LCFAs). Functionally, it has been identified as a member of a family of lipid-binding free fatty acid receptors including GPR40, GPR41, and GPR43. Upon stimulation by LCFAs, GPR120 can directly or indirectly modulate hormone secretion from the gastrointestinal tract and pancreas, and regulate lipid and/or glucose metabolism in adipose, liver, and muscle tissues. Additionally, GPR120 is postulated to mediate anti-inflammatory and insulin-sensitizing effects in adipose and macrophages. These benefits suggest that GPR120 agonists have the potential to be an effective treatment for obesity, type 2 diabetes mellitus (T2DM), and other metabolic syndromes.This article highlights and reviews research advances in this field that have been published in patent literature and peer-reviewed journals since 2014.Current development has been hindered by species differences in GPR120 distribution, differences in GPR120-mediated signaling in distinct tissue types, and lack of available ligands with suitable selectivity for GPR120 over GPR40 in both human and rodents. The discovery of β-arrestin biased GPR120 agonists will help elucidate the potential of selective therapeutics that may discriminate between desirable and undesirable pharmacological effects.ALA: α-linolenic acid; AUC: area under the curve; BRET: bioluminescence resonance energy transfer; CCK: cholecystokinin; CHO-K1 cell: Chinese hamster ovary-K1 cell; db/db mouse: diabetic mouse; DHA: docosahexaenoic acid; DIO: diet-induced obesity; DMSO: dimethyl sulfoxide; DPP-4: dipeptidyl peptidase 4; EPA: eicosapentaenoic acid; FA(s): fatty acid(s); FFA(s): free fatty acid(s); FFAR: free fatty acid receptor; FLIPR: fluorescent imaging plate reader; GIR: glucose infusion rate; GLP-1: glucagon-like peptide 1; GP(C)R: G protein-coupled receptor; GSIS: glucose-stimulated insulin secretion; HEK293 cell: human embryonic kidney 293 cell; HOMA-IR: homeostatic measurement assessment of insulin resistance; IP1: inositol phosphate turnover; IPGTT: intraperitoneal glucose tolerance test; LCFA(s): long-chain fatty acid(s); MEDmax: maximal efficacy; MIN6 cell: mouse insulin-secreting cell; NPY: neuropeptide Y; OGTT: oral glucose tolerance test; pERK: phosphorylated ERK; PPAR: peroxisome proliferator-activated receptor; QD: once daily; SAR: structure–activity relationship; siRNA: small interfering ribonucleic acid; STC-1: intestinal secretin tumor cell; T2DM: type 2 diabetes mellitus; U2OS cell: human bone osteosarcoma epithelial cell; uHTS: ultrahigh-throughput screening; ZDF: zucker diabetic fatty.

GPR120 agonists for the treatment of diabetes: a patent review (2014 present)

Evaluation of the insulin-releasing and glucose-lowering effects of GPR120 activation in pancreatic β-cells

Biological characteristics and agonists of GPR120 (FFAR4) receptor: the present status of research

G protein-coupled receptors: signalling and regulation by lipid agonists for improved glucose homoeostasis

Lipid receptors and islet function: therapeutic implications?

Progress of Research about G Protein-Coupled Receptor 120

Design, Synthesis, and Biological Evaluations of Phenylpropiolic Acid Derivatives As Novel GPR40 Agonists

G-Protein-Coupled Receptor 120-GPR120: Molecular Modeling Studies

Free fatty acid receptor GPR120 and pathogenesis of obesity and type 2 diabetes mellitus.

Positive interplay between FFAR4/GPR120, DPP-IV inhibition and GLP-1 in beta cell proliferation and glucose homeostasis in obese high fat fed mice

Current status of GPR40/FFAR1 modulators in medicinal chemistry (2016–2019): a patent review

An Updated Patent Review of GPR40/ FFAR1 Modulators (2020 – Present)

A Novel GPR120-selective Agonist Promotes Insulin Secretion and Improves Chronic Inflammation.

Fatty acid receptors as new therapeutic targets for diabetes

Advances of G protein coupled receptor 119 agonists and their structure-activity relationship

Optimization of GPR40 Agonists for Type 2 Diabetes.

GPR120: a Critical Role in Adipogenesis, Inflammation, and Energy Metabolism in Adipose Tissue

Free fatty acid receptor agonists for the treatment of type 2 diabetes: drugs in preclinical to phase II clinical development.

Targeting lipid GPCRs to treat type 2 diabetes mellitus — progress and challenges

Discovery of Benzofuran Propanoic Acid GPR120 Agonists: from Uhts Hit to Mechanism-Based Pharmacodynamic Effects.

Advances in Small-Molecule GPR40 Agonists for Treatment of Type 2 Diabetes Mellitus